{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:06:26Z","timestamp":1789632386697,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41401-026-01850-5","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:16:32Z","timestamp":1781590592000},"page":"2983-2995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A dual-antigen mRNA-lipid polyplex vaccine elicits durable multistage immunity and sterile protection against malaria in mice"],"prefix":"10.1038","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6804-864X","authenticated-orcid":false,"given":"Xiaoxing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jipin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-6966","authenticated-orcid":false,"given":"Zhenghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-470X","authenticated-orcid":false,"given":"Lubin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1850_CR1","unstructured":"World Health Organization. World malaria report: addressing inequity in the global malaria response. Geneva: World Health Organization; 2024."},{"key":"1850_CR2","unstructured":"De B The Value of Vaccination. New York: Springer; 2011."},{"key":"1850_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345.","journal-title":"Lancet"},{"key":"1850_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, Ou\u00e9draogo JB, Hamaluba M, Olotu A, et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024;403:533\u201344.","journal-title":"Lancet"},{"key":"1850_CR5","unstructured":"World Health Organization. Malaria vaccines: preferred product characteristics and clinical development considerations. Geneva: World Health Organization; 2022."},{"key":"1850_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6646","volume":"14","author":"JG Beeson","year":"2022","unstructured":"Beeson JG, Kurtovic L, Valim C, Asante KP, Boyle MJ, Mathanga D, et al. The RTS,S malaria vaccine: current impact and foundation for the future. Sci Transl Med. 2022;14:eabo6646.","journal-title":"Sci Transl Med"},{"key":"1850_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.chom.2017.07.003","volume":"22","author":"AF Cowman","year":"2017","unstructured":"Cowman AF, Tonkin CJ, Tham WH, Duraisingh MT. The molecular basis of erythrocyte invasion by malaria parasites. Cell Host Microbe. 2017;22:232\u201345.","journal-title":"Cell Host Microbe"},{"key":"1850_CR8","doi-asserted-by":"publisher","first-page":"2ra5","DOI":"10.1126\/scitranslmed.3000257","volume":"1","author":"SL Takala","year":"2009","unstructured":"Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med. 2009;1:2ra5.","journal-title":"Sci Transl Med"},{"key":"1850_CR9","doi-asserted-by":"publisher","first-page":"e1003943","DOI":"10.1371\/journal.ppat.1003943","volume":"10","author":"GJ Wright","year":"2014","unstructured":"Wright GJ, Rayner JC. Plasmodium falciparum erythrocyte invasion: combining function with immune evasion. PLoS Pathog. 2014;10:e1003943.","journal-title":"PLoS Pathog"},{"key":"1850_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature13715","volume":"515","author":"KE Wright","year":"2014","unstructured":"Wright KE, Hjerrild KA, Bartlett J, Douglas AD, Jin J, Brown RE, et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature. 2014;515:427\u201330.","journal-title":"Nature"},{"key":"1850_CR11","doi-asserted-by":"publisher","first-page":"20735","DOI":"10.1073\/pnas.1320771110","volume":"110","author":"M Wanaguru","year":"2013","unstructured":"Wanaguru M, Liu W, Hahn BH, Rayner JC, Wright GJ. RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum. Proc Natl Acad Sci USA. 2013;110:20735\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1850_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chom.2016.06.004","volume":"20","author":"JC Volz","year":"2016","unstructured":"Volz JC, Yap A, Sisquella X, Thompson JK, Lim NT, Whitehead LW, et al. Essential role of the PfRh5\/PfRipr\/CyRPA complex during Plasmodium falciparum invasion of erythrocytes. Cell Host Microbe. 2016;20:60\u201371.","journal-title":"Cell Host Microbe"},{"key":"1850_CR13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nature10606","volume":"480","author":"C Crosnier","year":"2011","unstructured":"Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature. 2011;480:534\u20137.","journal-title":"Nature"},{"key":"1850_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.chom.2008.06.001","volume":"4","author":"K Hayton","year":"2008","unstructured":"Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, Singh S, et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe. 2008;4:40\u201351.","journal-title":"Cell Host Microbe"},{"key":"1850_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.molbiopara.2012.12.005","volume":"187","author":"K Hayton","year":"2013","unstructured":"Hayton K, Dumoulin P, Henschen B, Liu A, Papakrivos J, Wellems TE. Various PfRH5 polymorphisms can support Plasmodium falciparum invasion into the erythrocytes of owl monkeys and rats. Mol Biochem Parasitol. 2013;187:103\u201310.","journal-title":"Mol Biochem Parasitol"},{"key":"1850_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S1473-3099(24)00312-8","volume":"24","author":"SE Silk","year":"2024","unstructured":"Silk SE, Kalinga WF, Salkeld J, Mtaka IM, Ahmed S, Milando F, et al. Blood-stage malaria vaccine candidate RH5.1\/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial. Lancet Infect Dis. 2024;24:1105\u201317.","journal-title":"Lancet Infect Dis"},{"key":"1850_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","volume":"2","author":"AM Minassian","year":"2021","unstructured":"Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, et al. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med. 2021;2:701\u201319.","journal-title":"Med"},{"key":"1850_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1473-3099(24)00752-7","volume":"25","author":"HM Natama","year":"2025","unstructured":"Natama HM, Salkeld J, Som\u00e9 A, Soremekun S, Diallo S, Traor\u00e9 O, et al. Safety and efficacy of the blood-stage malaria vaccine RH5.1\/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children. Lancet Infect Dis. 2025;25:495\u2013506.","journal-title":"Lancet Infect Dis"},{"key":"1850_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96381","volume":"2","author":"RO Payne","year":"2017","unstructured":"Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, et al. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight. 2017;2:e96381.","journal-title":"JCI Insight"},{"key":"1850_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.medj.2023.07.003","volume":"4","author":"SE Silk","year":"2023","unstructured":"Silk SE, Kalinga WF, Mtaka IM, Lilolime NS, Mpina M, Milando F, et al. Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. Med. 2023;4:668\u201386.","journal-title":"Med"},{"key":"1850_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567\u201371.","journal-title":"Nature"},{"key":"1850_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11095-022-03166-5","volume":"39","author":"J Di","year":"2022","unstructured":"Di J, Du Z, Wu K, Jin S, Wang X, Li T, et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm Res. 2022;39:105\u201314.","journal-title":"Pharm Res"},{"key":"1850_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-021-00634-z","volume":"6","author":"R Yang","year":"2021","unstructured":"Yang R, Deng Y, Huang B, Huang L, Lin A, Li Y, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021;6:213.","journal-title":"Signal Transduct Target Ther"},{"key":"1850_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","volume":"125","author":"S Persano","year":"2017","unstructured":"Persano S, Guevara ML, Li Z, Mai J, Ferrari M, Pompa PP, et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81\u20139.","journal-title":"Biomaterials"},{"key":"1850_CR25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.apsb.2022.11.013","volume":"13","author":"Z Chen","year":"2023","unstructured":"Chen Z, Meng C, Mai J, Liu Y, Li H, Shen H. An mRNA vaccine elicits STING-dependent antitumor immune responses. Acta Pharm Sin B. 2023;13:1274\u201386.","journal-title":"Acta Pharm Sin B"},{"key":"1850_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jconrel.2024.01.002","volume":"366","author":"L Huang","year":"2024","unstructured":"Huang L, Zhao F, He M, Fang Y, Ma X, Lu S, et al. An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants. J Control Release. 2024;366:479\u201393.","journal-title":"J Control Release"},{"key":"1850_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1651095","volume":"16","author":"MP Etna","year":"2025","unstructured":"Etna MP, Fuoco C, Severa M, Ricci D, Sinigaglia A, Lucca C, et al. A biomimetic model composed of injectable 3D muscle-like tissue, stromal and immune cells for recapitulating the rapid immune signature predictive of mRNA vaccine immunogenicity. Front Immunol. 2025;16:1651095.","journal-title":"Front Immunol"},{"key":"1850_CR28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nm1628","volume":"13","author":"S Chakravarty","year":"2007","unstructured":"Chakravarty S, Cockburn IA, Kuk S, Overstreet MG, Sacci JB, Zavala F. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat Med. 2007;13:1035\u201341.","journal-title":"Nat Med"},{"key":"1850_CR29","doi-asserted-by":"publisher","first-page":"e1004637","DOI":"10.1371\/journal.ppat.1004637","volume":"11","author":"AJ Radtke","year":"2015","unstructured":"Radtke AJ, Kastenm\u00fcller W, Espinosa DA, Gerner MY, Tse SW, Sinnis P, et al. Lymph-node resident CD8\u03b1+ dendritic cells capture antigens from migratory malaria sporozoites and induce CD8+ T cell responses. PLoS Pathog. 2015;11:e1004637.","journal-title":"PLoS Pathog"},{"key":"1850_CR30","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1016\/j.vaccine.2009.08.025","volume":"27","author":"NW Schmidt","year":"2009","unstructured":"Schmidt NW, Butler NS, Harty JT. CD8 T cell immunity to Plasmodium permits generation of protective antibodies after repeated sporozoite challenge. Vaccine. 2009;27:6103\u20136.","journal-title":"Vaccine"},{"key":"1850_CR31","doi-asserted-by":"publisher","first-page":"e1000877","DOI":"10.1371\/journal.ppat.1000877","volume":"6","author":"IA Cockburn","year":"2010","unstructured":"Cockburn IA, Chen YC, Overstreet MG, Lees JR, van Rooijen N, Farber DL, et al. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog. 2010;6:e1000877.","journal-title":"PLoS Pathog"},{"key":"1850_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.chom.2019.02.014","volume":"25","author":"SP Kurup","year":"2019","unstructured":"Kurup SP, Anthony SM, Hancox LS, Vijay R, Pewe LL, Moioffer SJ, et al. Monocyte-derived CD11c+ cells acquire Plasmodium from hepatocytes to prime CD8 T cell immunity to liver-stage malaria. Cell Host Microbe. 2019;25:565\u201377.","journal-title":"Cell Host Microbe"},{"key":"1850_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102372","volume":"67","author":"Y Fang","year":"2024","unstructured":"Fang Y, Li JX, Duangdany D, Li Y, Guo XL, Phamisith C, et al. Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos). EClinicalMedicine. 2024;67:102372.","journal-title":"EClinicalMedicine"},{"key":"1850_CR34","doi-asserted-by":"crossref","unstructured":"Tripathi AK, Mlambo G, Kanatani S, Sinnis P, Dimopoulos G Plasmodium falciparum gametocyte culture and mosquito infection through artificial membrane feeding. J Vis Exp. 2020;161.","DOI":"10.3791\/61426-v"},{"key":"1850_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2019.05.025","volume":"178","author":"DGW Alanine","year":"2019","unstructured":"Alanine DGW, Quinkert D, Kumarasingha R, Mehmood S, Donnellan FR, Minkah NK, et al. Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies. Cell. 2019;178:216\u201328.","journal-title":"Cell"},{"key":"1850_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-394","volume":"12","author":"X Zou","year":"2013","unstructured":"Zou X, House BL, Zyzak MD, Richie TL, Gerbasi VR. Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum. Malar J. 2013;12:394.","journal-title":"Malar J"},{"key":"1850_CR37","first-page":"52","volume":"68","author":"S Mellouk","year":"1990","unstructured":"Mellouk S, Berbiguier N, Druilhe P, Sedegah M, Galey B, Yuan L, et al. Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. Bull World Health Organ. 1990;68:52\u20139.","journal-title":"Bull World Health Organ"},{"key":"1850_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00345-0","volume":"6","author":"KL Mallory","year":"2021","unstructured":"Mallory KL, Taylor JA, Zou X, Waghela IN, Schneider CG, Sibilo MQ, et al. Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. NPJ Vaccines. 2021;6:84.","journal-title":"NPJ Vaccines"},{"key":"1850_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1615","volume":"2","author":"AD Douglas","year":"2011","unstructured":"Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun. 2011;2:601.","journal-title":"Nat Commun"},{"key":"1850_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/vaccines8040619","volume":"8","author":"WL Fotoran","year":"2020","unstructured":"Fotoran WL, Kleiber N, Glitz C, Wunderlich G. A DNA vaccine encoding Plasmodium falciparum PfRH5 in cationic liposomes for dermal tattooing immunization. Vaccines (Basel). 2020;8:619.","journal-title":"Vaccines (Basel)"},{"key":"1850_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","volume":"17","author":"AD Douglas","year":"2015","unstructured":"Douglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, Bartholdson SJ, et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe. 2015;17:130\u20139.","journal-title":"Cell Host Microbe"},{"key":"1850_CR42","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170210","volume":"9","author":"YD Mouwenda","year":"2024","unstructured":"Mouwenda YD, Jochems SP, Van Unen V, Betouke Ongwe ME, de Steenhuijsen Piters WAA, Stam KA, et al. Immune responses associated with protection induced by chemoattenuated PfSPZ vaccine in malaria-naive Europeans. JCI Insight. 2024;9:e170210.","journal-title":"JCI Insight"},{"key":"1850_CR43","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1056\/NEJMoa2313892","volume":"391","author":"OAC Lamers","year":"2024","unstructured":"Lamers OAC, Franke-Fayard BMD, Koopman JPR, Roozen GVT, Janse JJ, Chevalley-Maurel SC, et al. Safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite. N Engl J Med. 2024;391:1913\u201323.","journal-title":"N Engl J Med"},{"key":"1850_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00130-7","volume":"5","author":"L Kurtovic","year":"2024","unstructured":"Kurtovic L, Feng G, Hysa A, Haghiri A, O\u2019Flaherty K, Wines BD, et al. Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial. Lancet Microbe. 2024;5:100898.","journal-title":"Lancet Microbe"},{"key":"1850_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00577-8","volume":"7","author":"CTH Hayashi","year":"2022","unstructured":"Hayashi CTH, Cao Y, Clark LC, Tripathi AK, Zavala F, Dwivedi G, et al. mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum. NPJ Vaccines. 2022;7:155.","journal-title":"NPJ Vaccines"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01850-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01850-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01850-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:52:47Z","timestamp":1789631567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01850-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01850-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}